Latest Breaking News On - Rilpivirine long acting - Page 1 : comparemela.com

South Africa: HIV Treatment for Kids Has Improved and There Is More to Come, Says Dr Moherndran Archary

HIV treatment for children: Improvements and what's to come

GSK : and ViiV Healthcare to present scientific advancements in their industry-leading infectious diseases portfolio at IDWeek 2023 -October 10, 2023 at 07:17 am EDT

First scientific presentation of RSV vaccine efficacy and safety data over two seasons New public health impact modelling study data on meningococcal B.

GSK : to present updates on its industry-leading infectious disease portfolio at IDWeek 2022

First presentation of RSV Older Adult vaccine candidate s pivotal phase III efficacy and safety data New data showing Shingrix. | October 12, 2022

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

(2) Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ( GSK ), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines ViiV Healthcare s cabotegravir and Janssen s rilpivirine - dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiati